Heart failure hospitalization with DPP-4 inhibitors: A systematic review and meta-analysis of randomized controlled trials
Background: Heart failure hospitalization (hHF) with dipeptyl-dipeptidase-4 inhibitors (DPP-4Is) remains at the center stage since the publication of Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus – Thrombolysis in Myocardial Infarction (SAVOR-TIMI) in 2013 s...
Main Authors: | Awadhesh Kumar Singh, Ritu Singh |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2019;volume=23;issue=1;spage=128;epage=133;aulast=Singh |
Similar Items
-
The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01) -
Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study
by: Lui Ng, et al.
Published: (2021-07-01) -
National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
by: M. V. Shestakova, et al.
Published: (2023-12-01) -
Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01) -
SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
by: Noor Ul Amin, et al.
Published: (2022-11-01)